Cell therapy study for advanced lung cancer after treatment failure
Part of Cancer, Lungs & breathing clinical trials.
This Phase 1 trial tests a powerful “killing cell” therapy for people with advanced non-small cell lung cancer whose cancer did not respond to standard chemotherapy and targeted drugs. The goal is to see if this new treatment is safe and may work after other treatments have failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your life expectancy is at least 3 months (your doctor expects you can live at least that long).
- You have non-small cell lung cancer confirmed by biopsy or other lab testing.
- Your cancer has already failed standard chemotherapy and targeted therapy.
- Your general functioning is good (Karnofsky score 0–1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests GC101, a new cell-based treatment for non-small cell lung cancer in patients who have already tried other targeted drugs. The trial involves surgically removing some tumor tissue to grow immune cells in the lab, then infusing them back into your body to fight the cancer.
This trial tests a new combination therapy using your own immune cells (CAR-T and CAR-DC) that are specially trained to attack a protein called EphA2 found on your lung cancer cells. It is for people with advanced non-small cell lung cancer whose cancer has continued to grow after other treatments.
This study tests a new cell therapy (BST08) for people with advanced non-small cell lung cancer that has not improved after at least two prior treatments. The treatment is made from a sample of your own tumor, so it may be a personalized option for you.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This early-phase study tests immune cells given from a matched donor to treat advanced non-small-cell lung cancer. It aims to see how safe the treatment is and whether it can help control the cancer.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.